Radiopharmaceuticals:: From molecular imaging to targeted radionuclide therapy

被引：9

作者：

Schubiger, PA ^{[1
]}

Grünberg, J ^{[1
]}

Ametamey, SM ^{[1
]}

Honer, M ^{[1
]}

Garcia-Garayoa, E ^{[1
]}

Bläuenstein, P ^{[1
]}

Waibel, R ^{[1
]}

Novak-Hofer, I ^{[1
]}

Schibli, R ^{[1
]}

机构：

[1] ETH, PSI, Ctr Radiopharmacol Sci, CH-5232 Villigen, Switzerland

来源：

CHIMIA | 2004年 / 58卷 / 10期

关键词：

molecular imaging; PET-tracer; radioimmuno therapy; radionuclide therapy; radiopharmaceuticals;

D O I：

10.2533/000942904777677489

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

The research and development of smart radiodrugs is the goal of the Center of Radiopharmaceutical Science of ETH, PSI, and USZ. Positron Emission Tomography (PET) allows the non-invasive visualization of biochemical processes within the body. Radiolabeled PET-tracers allow the study of neurophysiological diseases like Alzheimer, Parkinson's disease or the imaging of metastatic tumors. PET-techniques are nowadays an important part of routine nuclear medicine diagnosis. Tumor-cell targeting biomolecules (e.g. antibodies or peptides) coupled to therapeutic radionuclides can sterilize the malignant cells while sparing healthy tissue. This so-called targeted radionuclide therapy has made tremendous progress in the recent years and the first approved radiotherapeutics are available for clinical use.

引用

页码：731 / 735

页数：5

共 50 条

[31] D-Peptide-based probes for CXCR4-targeted molecular imaging and radionuclide therapy
Cleeren, F.
Cawthorne, C.
Van Loy, T.
Kleynhans, J.
Leys, K.
Sathekge, M. M.
Schols, D.
Deroose, C. M.
Bormans, G.
[J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S266 - S267
[32] D-Peptide-Based Probe for CXCR4-Targeted Molecular Imaging and Radionuclide Therapy
Luyten, Kaat
Van Loy, Tom
Cawthorne, Christopher
Deroose, Christophe M.
Schols, Dominique
Bormans, Guy
Cleeren, Frederik
[J]. PHARMACEUTICS, 2021, 13 (10)
[33] In vitro model system for biological quality control and functional research of radiopharmaceuticals used for Targeted Radionuclide Therapy
Kalnina, Z.
Shvirksts, K.
Rubena, E. M.
Grube, M.
Kusins, T.
Kovaldins, R.
Mazkalnina, L.
Rozensteins, H.
Berzina, A.
Kizane, G.
Grinbergs, A.
[J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S682 - S683
[34] Nanotechnology for molecular imaging and targeted therapy
Wickline, SA
Lanza, GM
[J]. CIRCULATION, 2003, 107 (08) : 1092 - 1095
[35] Radiopharmaceuticals for targeted tumor diagnosis and therapy
Waibel, R
Novak-Hofer, I
Schibli, R
Bläuenstein, P
Garcia-Garayoa, E
Schwarzbach, R
Zimmermann, K
Pellikka, R
Gasser, O
Blanc, A
Brühlmeier, M
Schubiger, PA
[J]. CHIMIA, 2000, 54 (11) : 683 - 688
[36] Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors
Yordanova, Anna
Biersack, Hans-Juergen
Ahmadzadehfar, Hojjat
[J]. JOURNAL OF CLINICAL MEDICINE, 2020, 9 (11) : 1 - 16
[37] Molecular Imaging Without Radiopharmaceuticals?
Gore, John C.
Yankeelov, Thomas E.
Peterson, Todd. E.
Avison, Malcolm J.
[J]. JOURNAL OF NUCLEAR MEDICINE, 2009, 50 (06) : 999 - 1007
[38] Development of radiopharmaceuticals for molecular imaging
Saji, H
[J]. PET AND MOLECULAR IMAGING: STATE OF THE ART AND FUTURE PERSPECTIVES, 2004, 1264 : 139 - 147
[39] Targeted Radionuclide Therapy of Melanoma
Norain, Abdullah
Dadachova, Ekaterina
[J]. SEMINARS IN NUCLEAR MEDICINE, 2016, 46 (03) : 250 - 259
[40] Immunoliposomes for Targeted Radionuclide Therapy
Sgouros, G.
[J]. MEDICAL PHYSICS, 2009, 36 (06)

← 1 2 3 4 5 →